^
Association details:
| Biomarker: | Chr del(17p) |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Regimen: | FLAG-IDA (cytarabine + fludarabine IV + granulocyte-colony stimulating factor (GCSF) + idarubicin hydrochloride) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FLAG-IDA or venetoclax in previously treated TP53mut acute myeloid leukemia.
Published date:
05/25/2023
Excerpt:
We retrospectively analyzed 79 patients with AML and TP53mut or del17p...treated with front-line IC, and treated with either fludarabine-based therapy (with or without idarubicin, N = 15) or venetoclax + HMA (N = 10) in the subsequent line....Patients that received FLAG had significantly prolonged median overall survival compared to venetoclax + HMA (13.1 m. vs 4.5 m., p = 0.004)….In patients with del17p or TP53mut AML, FLAG-based salvage appears to offer a significant improvement in overall survival following IC failure.
DOI:
10.1200/JCO.2023.41.16_suppl.e19047
